HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications
Bruce RD, Dvoryak S, Sylla L, Altice FL. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications. International Journal Of Drug Policy 2007, 18: 326-328. PMID: 17689382, PMCID: PMC2084072, DOI: 10.1016/j.drugpo.2006.12.011.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance therapyInjection drug useAnti-retroviral therapySubstitution therapyDrug useAddition of methadoneAdministration of buprenorphineHIV-1 seropositivityOpiate substitution therapyOverall health outcomesIllicit drug useCost of buprenorphineHIV treatment accessMaintenance therapyOpioid dependenceHIV casesEntry criteriaTreatment accessBuprenorphineDrug usersHealth outcomesMultidisciplinary teamTherapyGlobal Fund resourcesAdministrationCase Series on the Safe Use of Buprenorphine/Naloxone in Individuals with Acute Hepatitis C Infection and Abnormal Hepatic Liver Transaminases
Bruce RD, Altice FL. Case Series on the Safe Use of Buprenorphine/Naloxone in Individuals with Acute Hepatitis C Infection and Abnormal Hepatic Liver Transaminases. The American Journal Of Drug And Alcohol Abuse 2007, 33: 869-874. PMID: 17994482, DOI: 10.1080/00952990701653875.Peer-Reviewed Original ResearchConceptsHepatitis C virusAcute hepatitis C infectionHepatitis C infectionBuprenorphine treatmentC infectionChronic viral illnessesSafety of buprenorphineAcute HCV infectionBuprenorphine/naloxoneOpiate substitution therapyOpioid-dependent patientsOpiate substitution treatmentLaboratory evaluationChronic hepatitisElevated transaminasesHCV infectionLiver transaminasesViral illnessCase seriesSubstitution therapyC virusSubstitution treatmentBuprenorphinePatientsTransaminase